Overview

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

Status:
Recruiting
Trial end date:
2027-06-14
Target enrollment:
0
Participant gender:
All
Summary
The study will determine the optimal dosing regimen of LNA043 in patients with knee osteoarthritis (OA).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:

- Males and females between 40 and 75 years of age

- Body mass index (BMI) < 40 kg/m2

- Diagnosis of primary tibiofemoral knee OA by standard American College of Rheumatology
clinical and radiographic criteria

- and other criteria as specified by the protocol

Exclusion Criteria:

- Participants with radiographic knee OA K-L grade = 4 on the non-target knee

- Arthroscopy of the target knee within the 6 months prior to Screening

- Hemoglobin < 8.5 g/dL (85 g/L) or platelet count < 100,000/μL

- and other criteria as specified by the protocol